Results 101 to 110 of about 9,912 (208)

Diabetes mellitus therapy adherence and therapy characterization in Northeast Portugal: classical vs dipeptidyl peptidase iv (dpp-4) inhibitors [PDF]

, 2017
Diabetes mellitus is a chronic disease characterizes by the absence of insulin production by the body or the inability of their effectively use. Aim: To determine prevalence of diabetes types, the frequency of glycemic control, identify change in eating
Pereira, Daniela, Pereira, Olívia R., Pinto, Isabel C., Pires, Sandra, Saldanha, Daniela   +4 more
core  

Weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experience

Vascular Health and Risk Management, 2010
James E Foley1, Jens Jordan21Clinical Research and Development, Novartis Pharmaceutical Corporation, East Hanover, New Jersey, USA; 2Institute for Clinical Pharmacology, Hannover Medical School, Hannover, GermanyAbstract: Various factors may confound how
James E Foley, Jens Jordan
doaj  

Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent [PDF]

, 2015

core   +1 more source

Inhibition of DPP-4 reduces acute mortality after myocardial infarction with restoration of autophagic response in type 2 diabetic rats [PDF]

, 2015

core   +1 more source

Vildagliptin promotes diabetic foot ulcer healing through autophagy modulation

Diabetology & Metabolic Syndrome
The study aimed to investigate the molecular mechanisms underlying the effects of Vildagliptin on the healing of diabetic foot ulcers (DFUs). The research compared patients who received 12 weeks of Vildagliptin treatment to those who did not.
Erik Biros, Venkat Vangaveti, Usman Malabu   +2 more
doaj   +1 more source

Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies

Vascular Health and Risk Management, 2011
Anja Schweizer1, Sylvie Dejager2, James E Foley3, Wolfgang Kothny31Novartis Pharma AG, Basel, Switzerland; 2Novartis Pharma SAS, Rueil-Malmaison, France; 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAAim: Analyzing safety aspects of a drug ...
Schweizer A, Dejager S, Foley JE, Kothny W   +3 more
doaj  

Vildagliptin is Effective for Glycemic Control in Diabetic Patients Undergoing either Hemodialysis or Peritoneal Dialysis [PDF]

, 2013

core   +1 more source

Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin

Vascular Health and Risk Management, 2013
Anja Schweizer,1 James E Foley,2 Wolfgang Kothny,2 Bo Ahrén31Novartis Pharma AG, Basel, Switzerland; 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 3Department of Clinical Sciences, Lund University, Lund, SwedenAbstract: Due to ...
Schweizer A, Foley JE, Kothny W, Ahrén B   +3 more
doaj  

A comparative study on vildagliptin brand and its generic equivalents using dissolution test as quality control measure tool

Scientific Reports
Market drugs including brand or generic with poor quality, don’t meet the acceptable standard guidelines. Vildagliptin is an important antidiabetic drugs used in monotherapy or in combinations protocols for treatment of diabetes mellites.
Ghadah H. Altoum, Fouza K. AL-Enazi, Mubarl M. Abudahash, Reem A. AL-Fadhli, Naif Alenzi   +4 more
doaj   +1 more source

Analgesic and anti-inflammatory effectiveness of sitagliptin and vildagliptin in mice [PDF]

, 2021
Cayasso, Mayella, László, F. János, Pórszász, Róbert, Szalai, Andrea, Ujhelyi, Judit Ágnes, Ujhelyi, Zoltán, Vecsernyés, Miklós   +6 more
core   +1 more source